Drug intelligence / Profile preview

TQA3810

Development stage: Phase 2
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQA3810 is a novel, highly selective small molecule oral agonist of Toll-like receptor 8 (TLR8). It is being developed by Chia Tai Tianqing Pharmaceutical Group for the treatment of chronic hepatitis B, both as monotherapy and in combination with nucleoside analogues. The drug acts by activating TLR8, which plays a role in modulating immune responses against viral infections. Clinical trials have evaluated its safety, tolerability, pharmacokinetics, and efficacy in patients with chronic hepatitis B.

Targets

TLR8 (Toll-like receptor 8)

Beyond the preview

Go deeper on TQA3810.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQA3810.

Explore the full profile